ABL Bio to Present Clinical Data for Two "Grabody-T" Bispecific Antibodies at ESMO 2026
Givastomig Phase 1b Expansion Data
Ragistomig Dose-Optimization Results to Be Presented
ABL Bio will present clinical results for two 4-1BB-based bispecific immuno-oncology drugs at Europe's largest oncology conference.
On Oct. 19, ABL Bio (CEO Lee Sang-hoon) said it will present clinical data for givastomig (ABL111) and ragistomig (ABL503) in poster presentations at the European Society for Medical Oncology Congress (ESMO 2026), to be held in Madrid, Spain, from Oct. 23 to 27 (local time).
Both candidates are part of a pipeline using Grabody-T, ABL Bio's proprietary 4-1BB-based bispecific antibody platform. Givastomig targets Claudin 18.2, which is overexpressed in cancers including gastric and pancreatic cancer, while ragistomig targets the immune checkpoint protein PD-L1. Both drugs are being jointly developed with U.S. biotechnology company Novabridge Biosciences.
Givastomig is currently in a Phase 2 clinical trial in combination with the PD-1 inhibitor nivolumab and chemotherapy. At the conference, ABL Bio will present updated data on the safety and efficacy of the combination therapy observed in a Phase 1b trial. Givastomig has received Fast Track designation and Orphan Drug designation from the U.S. Food and Drug Administration (FDA).
ABL Bio has expanded the ongoing Phase 1 trial of ragistomig by adding a monotherapy cohort for new cancer types, and has also begun evaluating its combination with a PD-1 inhibitor. At ESMO, the company plans to present Phase 1 monotherapy dose-optimization data under the title "Dose Optimization of Ragistomig, a PD-L1 x 4-1BB Bispecific Antibody."
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
ABL Bio is developing various nonclinical and clinical pipelines based on platforms including Grabody-B, a blood-brain barrier (BBB) shuttle platform, and Grabody-T. In addition to ABL111 and ABL503, ABL103, ABL105, ABL104, ABL206 and ABL209 are undergoing clinical trials in the United States, China, Australia, Japan and South Korea.
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.